Citius Oncology Inc's ROA from the third quarter of 2026 to the third quarter of 2025 and 5 Year Period

Return on Assets, Quarterly Results, Trends, Rankings, Statistics

What is Citius Oncology Inc's ROA in the third quarter of 2026?
Citius Oncology Inc recorded a cumulative net loss of $-46 million during 12 months ending in the third quarter of 2026, resulting in a negative return on assets (ROA) of -45.37%.

However, within the Healthcare sector 531 other companies had a higher return on assets. While Return on assets, overall ranking has advanced in the Jun 30 2026 quarter, so far to 3887, from total ROA ranking in the second quarter of 2026 at 5045.

What is ROA?

Select the Comparisons :

None ▼

Select the Ratio:

Return on Assets ROA▼

None ▼

Return on Assets ROA▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

Return On Assets	(Jun 30 2026) III. Quarter	(Mar 31 2026) II. Quarter	(Sep 30 2025) IV. Quarter	(Jun 30 2025) III. Quarter	(Mar 31 2025) II. Quarter
Y / Y Total Assets Change	23.13 %	343.51 %	2.23 %	-6.12 %	-37.3 %
Y / Y Net Income Change	-	-	-	-	-
Net Income (TTM) in million	-46	-45	-120	-120	-120
Return On Assets (TTM)	-45.37 %	-46.62 %	-157.46 %	-158.31 %	-154.57 %
TENKU's Total Ranking	# 3887	# 5045	# 4471	# 4596	# 4714
Total Assets (TTM) in million	112	101	101	91	91
Seq. Total Assets Change	11.31 %	0.16 %	10.11 %	0.3 %	300.97 %
Seq. Net Income Change	-	-	-	-	-

TENKU's 5 Years Annual ROA >> Back to TENKU Management Effectiveness >> Compare TENKU ROA to its Competitors

Return On Assets Company Ranking
Within:	No.
Industry	# 222
Sector	# 532
Overall	# 3836

Return On Assets Statistics
High	Average	Low
3.51 %	-78.04 %	-174.71 %
(Mar 31 2024)		(Mar 31 2025)

Financial Statements
Citius Oncology Inc's Assets	$ 112 million	TENKU's Balance sheet
Citius Oncology Inc's Income	$ -9 million	Quarterly TENKU's Income Statement
TENKU's Income by Division		See TENKU's Income by Division

Annual Return On Assets	(Dec 31 2025) FY 2025	(Dec 31 2024) FY 2024	(Dec 31 2023) FY 2023	(Dec 31 2022) FY 2022	FY
Y / Y Total Assets Change	22.08 %	-37.96 %	109.84 %	-	-
Total Assets in million	110	90	145	69	0
Y / Y Net Income Change	-	-	535.3 %	-	-
Net Income in million	-6	-7	2	0	0
Annual Return On Assets	-5.03 %	-7.39 %	1.67 %	0.55 %	-

TENKU's 5 Years Annual ROA >> Back to TENKU Management Effectiveness >> Compare TENKU ROA to its Competitors

More Return On Assets Ratios
TENKU's' Return on Assets at Yahoo Finance
Major Pharmaceutical Preparations Industry Return On Assets Trends and Statistics
Healthcare Sector Roa Statistics
Roa Trends for overall market
TENKU's Roa Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and overall Market
Highest Ranking Return On Assets
Lowest Ranking Return On Assets
Subscribers only: Roa for TENKU's Competitors
Subscribers only: Roa for Citius Oncology Inc's Suppliers
Subscribers only: Return On Assets for TENKU's Customers

You may also want to know
TENKU's Roi	TENKU's Inventory Turnover Ratio	TENKU's Growth Rates	TENKU's Dividend Comparisons
	TENKU's Profitability Ratios	TENKU's Asset Turnover Ratio	TENKU's Dividend Growth
TENKU's Roe	TENKU's Valuation Ratios	TENKU's Financial Strength Ratios	TENKU's Dividend Payout Ratio

Companies with similar Return On Assets at Jun 30 2026, within Healthcare Sector

ROA

Date modified: 2026-09-26T07:42:28+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.